Abbott Laboratories (NYSE:ABT) Given New $113.00 Price Target at The Goldman Sachs Group

Abbott Laboratories (NYSE:ABT) had its price target decreased by investment analysts at The Goldman Sachs Group from $121.00 to $113.00 in a research report issued on Wednesday,MarketScreener reports. The firm currently has a “buy” rating on the healthcare product maker’s stock. The Goldman Sachs Group’s price target would suggest a potential upside of 31.31% from the stock’s current price.

A number of other equities research analysts have also commented on ABT. TD Cowen reduced their price target on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Stifel Nicolaus decreased their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. BTIG Research restated a “buy” rating and issued a $131.00 price target on shares of Abbott Laboratories in a research report on Monday, April 27th. Leerink Partners dropped their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Finally, UBS Group dropped their price target on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $119.09.

Abbott Laboratories Trading Down 0.7%

Shares of Abbott Laboratories stock opened at $86.05 on Wednesday. The firm’s 50 day moving average is $95.89 and its 200 day moving average is $111.43. The firm has a market capitalization of $149.89 billion, a PE ratio of 24.12, a price-to-earnings-growth ratio of 1.46 and a beta of 0.65. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same quarter last year, the business posted $1.09 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by corporate insiders.

Institutional Trading of Abbott Laboratories

Several institutional investors have recently made changes to their positions in the business. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. Purpose Unlimited Inc. bought a new stake in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories during the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.